Asia Pacific Protein Binding Assay Market Growth and Recent Trends by 2028

Asia Pacific Protein Binding Assay Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (Equilibrium Dialysis, Ultracentrifugation, Ultrafiltration, Surface Plasmon, and Others) and End User (Contract Research Organization, Pharmaceutical & Biotechnology Companies, and Research & Diagnostic Laboratories)

Historic Data: 2019-2020 | Base Year: 2021 | Forecast Period: 2022-2028

Status : Published
Report Code : TIPRE00025439

Category : Life Sciences
No. of Pages : 81

Available Report Formats :

Asia Pacific Protein Binding Assay Market Growth and Recent Trends by 2028

Report Date: Oct 2021 | Report Code: TIPRE00025439 Email: sales@theinsightpartners.com

Analysis Strategic Insights Market Drivers Report Scope Recent Developments FAQs

The protein binding assay market in APAC is expected to grow from US$ 73.34 million in 2021 to US$ 153.72 million by 2028; it is estimated to grow at a CAGR of 11.2% from 2021 to 2028.

China, Japan, and India are major economies in APAC. Label-Free receptor assays to emerge as powerful assay platform in coming years is the major factor driving the growth of the APAC protein binding assay market. The development of pharmacological assays has resulted in the discovery of a wide range of receptor and drug molecule cellular behavior. Label-free receptor assays are growing rapidly as a powerful assay platform for studying receptor signaling and identifying critical nodes in receptor signaling networks. Drug molecules can now be categorized and characterized in novel ways due to label-free receptors. With substantial advances in biosensor instrumentation, such as the Epic system, high throughput screening of drug molecules operating on native cells, including primary cells, has become a reality. Traditional label-based techniques, such as fluorescence, are being replaced by label-free detection of molecular interactions. The label-free technique is preferred to avoid molecular labels when functional information is required. This is especially true for protein targets where labels can compromise the function of a protein. Label-free methods are compatible with real-time detection, allowing for the assessment of the rates of interacting molecules' association and dissociation. Several label-free approaches are currently available for the detection of biomolecular interactions, based on technologies—such as interferometry, diffraction, surface plasmon resonance (SPR), and quartz crystal microbalance. SPR detection is the most extensively used of them. Thus, label-free assays, which evaluate the interaction of molecules (antibodies-antigens, ligands-receptors, proteins-proteins) without the use of tags such as fluorescent dyes or radioisotopes, are expected to become a powerful assay platform in the future years, which is further anticipated to drive the market in APAC.

According to Worldometer, from its epicenter in China, SARS-CoV-2 has spread to infect ~58,231,688 people in Asia, as of July 29, 2021. Following the terrible loss of lives, economies in Asia Pacific have collapsed during the pandemic. The pandemic has emphasized health data exchange and interoperability under a microscope. The supply chain disruptions, along with the tremendous demand for efficient treatments against COVID-19, have put the healthcare research industry in a crucial situation in region. Socioeconomics in countries such as India, China, Japan, and South Korea were severely affected, resulting in rise in inflation, decrease in GDP, and surge in unemployment.Countries such as China, Japan, Singapore, and South Korea show large interest in clinical trials. High costs in western countries drives the flow of medical affairs outsourcing to Asia Pacific. Moreover, pharmaceutical companies are becoming aware of new and changing regulatory environments for drugs, devices, and in vitro diagnostics to expand sales to the Asian market. Asian countries have been at a forefront of updating GMP standards and medical device regulatory systems and introducing drug price controls. Third-party guidance and advice are required as part of any acquisition or any improvement of current standards. Increasingly, third-party outsourcing service providers are playing a greater role in supporting the protein binding assay market progress in Asia Pacific.

This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

APAC Protein Binding Assay Market Segmentation

APAC Protein Binding Assay Market – By Technology

Equilibrium Dialysis
Ultracentrifugation
Ultrafiltration
Surface Plasmon
Others

APAC Protein Binding Assay Market – By End User

Contract Research Organization
Pharmaceutical and Biotechnology Companies
Research and Diagnostic Laboratories

APAC Protein Binding Assay Market– By Country

China
Japan
India
Australia
South Korea
Rest of APAC

APAC Protein Binding Assay Market-Companies Mentioned

Biotium, Inc
Eurofins Scientific
General Electric Company
MERCK KGaA
MicroConstants, Inc
Pharmaron Beijing Co., Ltd
Sartorius AG
SOVICELL GMBH
THERMO FISHER SCIENTIFIC INC.

Asia Pacific Protein Binding Assay Report Scope

Report Attribute	Details
Market size in 2021	US$ 73.34 Million
Market Size by 2028	US$ 153.72 Million
CAGR (2021 - 2028)	11.2%
Historical Data	2019-2020
Forecast period	2022-2028
Segments Covered	By Technology Equilibrium Dialysis Ultracentrifugation Ultrafiltration Surface Plasmon By End User Contract Research Organization Pharmaceutical & Biotechnology Companies Research & Diagnostic Laboratories
Regions and Countries Covered	Asia-Pacific China India Japan Australia Rest of Asia-Pacific
Market leaders and key company profiles	Biotium, Inc Eurofins Scientific General Electric Company MERCK KGaA MicroConstants, Inc Pharmaron Beijing Co., Ltd Sartorius AG SOVICELL GMBH THERMO FISHER SCIENTIFIC INC.

Research Manager

Mrinal Kerhalkar

Manager,
Market Research & Consulting

Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

What are the Asia Pacific Protein Binding Assay Market report deliverables?

Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
PEST and SWOT Analysis
Market Size Value / Volume - Regional, Country
Industry and Competitive Landscape
Excel Dataset

Recent Reports

Testimonials

The Insight Partners' SCADA System Market report is comprehensive, with valuable insights on current trends and future forecasts. The team was highly professional, responsive, and supportive throughout. We are very satisfied and highly recommend their services.

RAN KEDEM Partner, Reali Technologies LTDs

I requested a report on a very specific software market and the team produced the report in a few days. The information was very relevant and well presented. I then requested some changes and additions to the report. The team was again very responsive and I got the final report in less than a week.

JEAN-HERVE JENN Chairman, Future Analytica

We worked with The Insight Partners for an important market study and forecast. They gave us clear insights into opportunities and risks, which helped shape our plans. Their research was easy to use and based on solid data. It helped us make smart, confident decisions. We highly recommend them.

PIYUSH NAGPAL Sr. Vice President, High Beam Global

The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services

YUKIHIKO ADACHI CEO, Deep Blue, LLC.

This is the first time I have purchased a market report from The Insight Partners.While I was unsure at first, I visited their web site and felt more comfortable to take the risk and purchase a market report.I am completely satisfied with the quality of the report and customer service. I had several questions and comments with the initial report, but after a couple of dialogs over email with their analyst I believe I have a report that I can use as input to our strategic planning process.Thank you so much for taking the extra time and making this a positive experience.I will definitely recommend your service to others and you will be my first call when we need further market data.

JOHN SUZUKI President and Chief Executive Officer, Board Director, BK Technologies

I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.

DR CHIJIOKE ONYIA MANAGING DIRECTOR, PineCrest Healthcare Ltd.

Reason to Buy